PATENT CLAIM ANALYSIS

Application Number: 15775647
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "171000"]

Abstract:
Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for treating inflammatory and autoimmune diseases, including but not limited to lupus, are disclosed.

Claim (Index 27):
The method of  claim 26 , wherein said disease or disorder is selected from the group consisting of systemic lupus erythematosus, lupus nephritis, minimal change disease, focal segmental glomerulosclerosis, IgA nephropathy, transplant rejection, rheumatoid arthritis, osteoarthritis, psoriasis, ankylosing spondylitis, vasculitis, multiple sclerosis, systemic sclerosis, gout, uveitis, asthma, cystic fibrosis, chronic obstructive pulmonary disease, atopic dermatitis (eczema), sepsis, inflammatory bowel disease, trauma brain injury, spinal cord injury, ischemia reperfusion injury, heterotopic ossification, and granuloma.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.39474
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13837195', '11996009', '14448998', '14670425', '14670422']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.776137326931371
- 35 USC 102 Novelty (BERT): 0.4969308773831811
- Combined Prediction Score: 0.7482166819765521
- Mean Citation Score: 234.029932
- Max Citation Score: 241.24754
- Similarity Product: 172.3711396741688

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test